BioCentury | Jun 17, 2013
Company News

Zeria, Astellas sales and marketing update

...Astellas launched Acofide acotiamide in Japan to treat functional dyspepsia. The National Health Insurance (NHI) list...
BioCentury | Apr 1, 2013
Clinical News

Acofide acotiamide regulatory update

...Zeria and Astellas said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Acofide acotiamide to...
...Tokyo:4559), Tokyo, Japan Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Acofide acotiamide ( Z-338 , YM443...
BioCentury | Feb 18, 2013
Clinical News

Acotiamide regulatory update

...Astellas said a Japanese advisory committee recommended approval of acotiamide to treat alcohol dependence. The company...
...Ltd. (Tokyo:4559), Tokyo, Japan Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Acotiamide ( Z-338 , YM443...
BioCentury | Jul 5, 2010
Finance

2H10 milestones

...diabetes Ph III data 3Q10 Zeria Pharmaceutical Co. Ltd. (Tokyo:4559)/Astellas Pharm Inc. (Tokyo:4503) Acotiamide (Z-338, YM443...
BioCentury | Jul 5, 2010
Clinical News

Acotiamide: Phase III data

...In a double-blind, Japanese Phase III trial in 897 patients, thrice-daily 100 mg oral acotiamide met...
...early satiety at week 4 vs. placebo. P-values were not disclosed. Zeria also said that acotiamide...
...Ltd. (Tokyo:4559), Tokyo, Japan Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Acotiamide ( Z-338 , YM443...
BioCentury | Mar 8, 2004
Strategy

The Fuji-Yama merger

...YM087) Chronic heart failure Ph II (EU, U.S.) Yamanouchi FK614 Diabetes Ph II (U.S.) Fujisawa YM443...
Items per page:
1 - 6 of 6